FOLH1 and prostate carcinoma: [177Lu]Lutetium labelled with somatostatin analogs and prostate-specific membrane antigen (PSMA) are generally used for the treatment of soft-tissue and bone metastases of neuroendocrine tumors and prostate cancer, respectively, revealing acceptable response rates [15,16].